|
|
| OTC Healthcare in Australia |
|
| Published : 2007/11 |
| In 2006, OTC healthcare sales in Australia continued to grow steadily, despite some cough, cold and allergy remedies switching from S2 to S3 classification. The key factors that led to growth in sales were the rising obesity numbers, the increase in the n ... |
| OTC Healthcare in Thailand |
|
| Published : 2007/11 |
| Thailand' s new government was installed by the military following a coup d' etat in September 2006. A rise in household debt, coupled with a sharp drop in consumer confidence, contributed to a slowdown in economic growth. ... |
| Outsourcing Drug Discovery: China and India |
|
| Published : 2007/11 |
| Driven by the need to improve R&D productivity and effi ciency and the desire to access untapped markets, global pharmaceutical companies have increasingly offshored and outsourced operations to CROs in China and India. A wide array of factors, however, c ... |
| Practical Guide to Finding Partners in Biopharma |
|
| Published : 2007/11 |
| The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering pro ... |
| Recordati: Performance, Products, Pipeline and Potential |
|
| Published : 2007/11 |
| Recordati is engaged in the research, development, manufacture and marketing
of pharmaceuticals and pharmaceutical chemicals. In 2002, total sales reached
?492.7 million, an increase of 13.7% over the previous year ... |
| RNAi Therapeutics 2008 Market Report |
|
| Published : 2007/11 |
| This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. ... |
| Schering-Plough Corporation: PharmaVitae Profile |
|
| Published : 2007/11 |
| This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharmaceutical sector. It encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales f ... |
| The Anti-Migraine Market 2007-2022 |
|
| Published : 2007/11 |
| The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC drugs. The report also focuses on the technological issues, including the latest trends, patents, new products and other influential factor ... |
| The Pharma R&D Fact Book 2007 |
|
| Published : 2007/11 |
| Utilising daily-updated data, plus an extensive new review of R&D investment, this essential report examines the research investment and drug pipelines for 39 leading companies. ... |
| The Pharmaceutical Market: Argentina |
|
| Published : 2007/11 |
| Argentina is the third largest pharmaceutical market in Latin America, after Mexico and Brazil, although Venezuela is catching up. Mexico and Brazil offer more incentives for multinationals to set up their regional subsidiaries. As a result, some internat ... |
| The Pharmaceutical Market: Ireland |
|
| Published : 2007/11 |
| Many large pharmaceutical companies have a manufacturing base in Ireland. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market pr ... |
| The Pharmaceutical Market: Pakistan |
|
| Published : 2007/11 |
| Healthcare in Pakistan is still in the early stages of development. Widespread poverty and a weak health system underlie the poor health status of the population. This report is ideal for executives wanting to understand the key drivers in the pharmaceuti ... |
| The Pharmaceutical Market: Slovenia |
|
| Published : 2007/11 |
| This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. ... |
| UCB S.A.: PharmaVitae Profile |
|
| Published : 2007/11 |
| This analysis examines the historical and forecast performance for UCB in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales fore ... |
| Who's Developing What in New Cancer Drugs 2007? |
|
| Published : 2007/11 |
| The new 6th edition of this respected management report is the essential reference work for everyone in the field. The report covers 121 companies - from the largest blue-chip multinational to smaller specialist organisations - and all phases of developme ... |
| Analgesics in Norway |
|
| Published : 2007/10 |
| Euromonitor International's Analgesics in Norway report offers a comprehensive guide to the size and shape of the market at a national level. ... |
| Barr: PharmaVitae Generics Profile |
|
| Published : 2007/10 |
| This analysis examines the historical and forecast performance for Barr in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance. ... |
| Biosimilars: a market coming of age? |
|
| Published : 2007/10 |
| Despite the lack of progress in the regulatory situation in the US, the biosimilars sector is forging ahead as generic companies gain ground in this high-reward/high-risk business. ... |
| Brands & Strategies: Osteoporosis |
|
| Published : 2007/10 |
| The osteoporosis market has traditionally been dominated by the bisphosphonate drug class, championed by Merck' s once-weekly Fosamax (alendronate) and Procter & Gamble[P&G]/Sanofi-Aventis' Actonel (risedronate). This will change dramatically over the for ... |
| Brands & Strategies: Type 2 Diabetes |
|
| Published : 2007/10 |
| In 2006, the type 2 diabetes market, valued at over $12 billion in the US, Europe, and Japan, was dominated by the two blockbuster PPAR-gamma agonists, ... |
|
|
Top
View Cart